This week we saw the approval of a new molecular entity by the FDA along with the first marketing authorization approval for a genetic health risk assessment. Here is my recap of the top regulatory news stories for this week: The FDA approved TaiMed Biologics’ Trogarzo (ibalizumab-ulyk) for the treatment of adults with chronic HIV[…]